XOMA Royalty - 8.625% PRF PERPETUAL USD 25 - Ser A Long Term Debt

As of the most recent data (March 2026), XOMAP shows a long-term debt of $110M. That compares with $100M in the prior-year period — up 8.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, XOMAP's long-term debt is now $110M (was $100M) — a 8.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether XOMA Royalty - 8.625% PRF PERPETUAL USD 25 - Ser A is outperforming or lagging.

Tracking XOMAP's long-term debt over time shows whether XOMA Royalty - 8.625% PRF PERPETUAL USD 25 - Ser A is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $100M in the prior-year period — up 8.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has XOMA Royalty - 8.625% PRF PERPETUAL USD 25 - Ser A's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $110M) with ownership activity and broader fundamentals.

XOMA Royalty - 8.625% PRF PERPETUAL USD 25 - Ser A's long-term debt is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.